IgA nephropathy trials in Mexico

2 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

• Phase 3Taking people
  A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

  Where

  Benito Juárez, Querétaro

  Age

  18 years to 100 years

  People

  540 worldwide

  Run by

  Novartis Pharmaceuticals

  See details and how to joinNCT04557462 · EU 2023-508690-92-00
• Phase 3Taking people
  Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.

  Where

  Monterrey

  Age

  18 years to 100 years

  People

  220 worldwide

  Run by

  Novartis Pharmaceuticals

  See details and how to joinNCT06858319